Nexavar (sorafenib), the first ORAL drug for advanced kidney cancer
September 2006
Health Canada has approved Nexavar (sorafenib), the first ORAL drug for advanced kidney cancer.
Nexavar slows the cancer's progression. It can delay death by about 3 months.
It slows tumour growth by cutting off the blood supply to the tumour.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote